Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
Open accessThe DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) plays vital roles in cellular processes including cell proliferation, survival, motility, and differentiation. The dysregulated activation of the receptor is often implicated in human cancers. EGFR is synthesized as a single-pass transmembrane protein, which consists of an extracellular ligand-binding domain and an intracellular kinase domain separated by a single transmembrane domain. The receptor is activated by a variety of polypeptide ligands such as epidermal growth factor and transforming growth factor α. It has long been thought that EGFR is activated by ligand-induced dimerization of the receptor monomer, which brings intracellular kinase domains into close proximity for trans-autophosphorylation. An increasing number of diverse studies, however, demonstrate that EGFR is present as a pre-formed, yet inactive, dimer prior to ligand binding. Furthermore, recent progress in structural studies has provided insight into conformational changes during the activation of a pre-formed EGFR dimer. Upon ligand binding to the extracellular domain of EGFR, its transmembrane domains rotate or twist parallel to the plane of the cell membrane, resulting in the reorientation of the intracellular kinase domain dimer from a symmetric inactive configuration to an asymmetric active form (the “rotation model”). This model is also able to explain how oncogenic mutations activate the receptor in the absence of the ligand, without assuming that the mutations induce receptor dimerization. In this review, we discuss the mechanisms underlying the ligand-induced activation of the preformed EGFR dimer, as well as how oncogenic mutations constitutively activate the receptor dimer, based on the rotation model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · cited 2×
“Two other mutations are a deletion in which residues from L747 to P753 (L723–P729 in mature EGFR) are replaced with a single serine to give the ∆L747–P753insS mutant [133,135,136], and the mutant ∆S752–I759 (∆S728–I735 in mature EGFR) in which residues 752–759 are deleted [133].”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“All these cysteines are present in Subdomain IV [113,124-126].”
BackgroundSignal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · cited 1×
“Ligand binding to the extracellular domain shifts the equilibrium toward the formation of active dimers, and induces kinase stimulation [33-35].”
BackgroundThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · cited 1×
“Recent genomic studies in GBM and NSCLC patients have identified an additional class of oncogenic mutations caused by deletion of C-terminal coding regions [103,154-156].”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Furthermore, a modified model has proposed that the receptor monomers are at equilibrium with receptor dimers [33,34].”
BackgroundERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170 · cited 8×
“Deletion mutants in the intracellular domain have also been found in NSCLC, and various deletions within the range encompassing E746 to I759 (E722 to I735 in mature EGFR) have been identified [133].”
BackgroundInfluentialUllrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752 · cited 1×
“EGFR is a single-pass transmembrane protein, consisting of an extracellular domain, a transmembrane domain, a juxtamembrane (JM) segment, a kinase domain, and a C-terminal regulatory tail (Figure 1) [8,9].”
BackgroundOlayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434 · cited 1×
“EGFR is involved in a variety of cellular processes including cell proliferation, motility, survival and differentiation, and is essential for normal animal development [1-4].”
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143 · cited 1×
“Enhanced EGFR levels have been correlated with poor prognosis in various cancers including head and neck, bladder, ovarian, cervical, and esophageal cancers [99].”
BackgroundThe Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817 · cited 1×
“EGFR activates several downstream signaling cascades, which include pathways mediated by Ras/Raf/MAP kinase, phosphoinositide-3-kinase (PI3K)/Akt, and phospholipase Cγ [10,24].”
BackgroundMapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · cited 1×
“Among them, mutants with a deletion of exon 25 (from G983 to L1038; from G959 to L1014 in mature EGFR) or both exons 25 and 26 (from G983 to G1054; from G959 to G1030 in mature EGFR, which is equivalent to EGFRvIVb above) are constitutively phosphorylated, and cause phosphorylation of downstream STAT3 when expressed i…”
BackgroundThe Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752 · cited 1×
“Upon activation, helix αC rotates toward the active site, inducing an open conformation of the A-loop that allows substrate binding [63,64,67].”
BackgroundAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 4×
“Side chains of both L858 and L861 contribute to a hydrophobic core formed by residues from the helix αC, the A-loop, and elsewhere [64,146].”
BackgroundInfluentialEpidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353 · cited 1×
“Excellent reviews have recently been published on the mechanism of activation of EGFR based on the ligand-induced dimerization model [25-29].”
BackgroundCrystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227 · cited 2×
“of Subdomain IV are positioned to interact one another to form a back-to-back, dimeric complex (Figure 2b) [14,15].”
BackgroundYun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192 · cited 2×
“G719 contributes to interactions that hold helix αC in the inactive conformation [130].”
BackgroundTargeted Disruption of Mouse EGF receptor: Effect of Genetic Background on Mutant Phenotype
Threadgill, D. W., Dlugosz, A. A., Hansen, L. A., Tennenbaum, T., Lichti, U., Yee, D., LaMantia, C., Mourton, T., Herrup, K., Harris, R. C., et al. (1995) · Science · doi:10.1126/science.7618084 · Cited by 1,179 · cited 1×
“EGFR is involved in a variety of cellular processes including cell proliferation, motility, survival and differentiation, and is essential for normal animal development [1-4].”
BackgroundA Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122 · cited 1×
“Side chains of both L858 and L861 contribute to a hydrophobic core formed by residues from the helix αC, the A-loop, and elsewhere [64,146].”
BackgroundEpithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
Miettinen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z., & Derynck, R. (1995) · Nature · doi:10.1038/376337a0 · Cited by 1,039 · cited 1×
“EGFR is involved in a variety of cellular processes including cell proliferation, motility, survival and differentiation, and is essential for normal animal development [1-4].”
BackgroundStrain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor
Sibilia, M., & Wagner, E. F. (1995) · Science · doi:10.1126/science.7618085 · Cited by 1,002 · cited 1×
“EGFR is involved in a variety of cellular processes including cell proliferation, motility, survival and differentiation, and is essential for normal animal development [1-4].”
BackgroundLigand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor
Schlessinger, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00966-2 · Cited by 993 · cited 1×
“It has long been thought that the two classes would be EGFR monomers and dimers with low and high affinity, respectively [68,69].”
BackgroundErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · cited 2×
“The aberrant activation of EGFR is implicated in a variety of human cancers [5].”
BackgroundAn Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909 · cited 1×
“The extracellular ligand-binding domain of EGFR contains four distinct Subdomains I-IV [11-15].”
BackgroundStructural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853 · cited 3×
“The EGFR type I mutant, EGFRvI, lacks most of the extracellular domain, and is tumorigenic (Figure 1) [112].”
BackgroundWong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849 · cited 9×
“Mutations in the C-Terminal Tail Region As described above, a large fraction of GBM cells display EGFR gene amplification that correlates with receptor overexpression [102], and also exhibit an EGFRvIII deletion mutation in the extracellular domain of the receptor [150].”
BackgroundInfluentialEGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J., & Lemmon, M. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00047-9 · Cited by 801 · cited 4×
“How is the EGFR dimer activated by ligand binding? It is known that the EGFR dimer is formed through an interaction of the intracellular domain [38,48], the transmembrane domain [83,84], and the extracellular C-terminal region of Subdomain IV [58,62].”
BackgroundInfluentialGarrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
Harris, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00105-2 · Cited by 776 · cited 1×
“The receptor is activated by the binding of various ligands including epidermal growth factor (EGF), transforming growth factor α (TGFα), amphiregulin (AREG), epigen, β-cellulin, heparin-binding EGF (HB-EGF), and epiregulin [6,7].”
BackgroundEGFR Mutations in Lung Cancer: Correlation With Clinical Response to Gefitinib Therapy
Tanoue, L. T. (2006) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70092-6 · Cited by 776
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Insulin interactions with its receptors: Experimental evidence for negative cooperativity
De Meyts, P., Roth, J., Neville, D. M., Gavin, J. R., & Lesniak, M. A. (1973) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(73)80072-5 · Cited by 721 · cited 1×
“Similarly, the analysis of insulin binding to the insulin receptor also reveals curvilinear (concave-up) Scatchard plots due to a negative cooperative interaction between insulin and its receptor, which has a covalently cross-linked dimeric structure with cysteine disulfide bridges [73].”
BackgroundOncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
Greulich, H., Chen, T.-H., Feng, W., Jänne, P. A., Alvarez, J. V., Zappaterra, M., Bulmer, S. E., Frank, D. A., Hahn, W. C., Sellers, W. R., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020313 · Cited by 677 · cited 1×
“Mutations in the kinase domain The G719S mutation (G695S in mature EGFR) also activates the kinase presumably by destabilization of the symmetric inactive configuration of the dimer [127-129].”
BackgroundPrenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673 · cited 1×
“The epidermal growth factor receptor plays crucial roles in cellular processes such as cell proliferation and differentiation, and its aberrant activation is implicated in a variety of human cancers [5,95].”
BackgroundSomatic mutations of epidermal growth factor receptor signaling pathway in lung cancers
Shigematsu, H., & Gazdar, A. F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21496 · Cited by 657 · cited 8×
“Deletion mutants in the intracellular domain have also been found in NSCLC, and various deletions within the range encompassing E746 to I759 (E722 to I735 in mature EGFR) have been identified [133].”
BackgroundInfluentialHunter, T., Ling, N., & Cooper, J. A. (1984) · Nature · doi:10.1038/311480a0 · Cited by 645 · cited 1×
“It has long been recognized that phosphorylation of EGFR T678 (T654 in mature EGFR) leads to decreased affinity of EGF and loss of EGF-stimulated receptor autophosphorylation [78-82].”
BackgroundYarden, Y., & Schlessinger, J. (1987) · Biochemistry · doi:10.1021/bi00379a035 · Cited by 627 · cited 1×
“The epidermal growth factor receptor was one of the first receptors for which ligand-induced dimerization was proposed as the molecular mechanism of transmembrane signaling [30,31].”
BackgroundMechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 606 · cited 10×
“Exon 25 encodes 56 amino-acid residues from G983 to L1038 (from G959 to L1014 in mature EGFR), and encompasses the AP-2 helix and the electrostatic hook, which are involved in stabilization of the symmetric inactive configuration of the kinase dimer [63].”
BackgroundInfluentialEkstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602 · cited 1×
“EGFRvIVa lacks exons 25–27 (from G983 to P1090; from G959 to P1066 in mature EGFR), and EGFRvIVb lacks exons 25 and 26 (from G983 to G1054; from G959 to G1030 in mature EGFR) [113,151,152].”
BackgroundHuang, H.-J. S., Nagane, M., Klingbeil, C. K., Lin, H., Nishikawa, R., Ji, X.-D., Huang, C.-M., Gill, G. N., Wiley, H. S., & Cavenee, W. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.5.2927 · Cited by 595 · cited 1×
“Only limited numbers of substrate tyrosine residues seem to be phosphorylated [120].”
BackgroundSpatial control of EGF receptor activation by reversible dimerization on living cells
Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010) · Nature · doi:10.1038/nature08827 · Cited by 538 · cited 2×
“As discussed above, this transition seems to occur between EGFR dimers and tetramers [54,55].”
BackgroundKnebel, A., Rahmsdorf, H. J., Ullrich, A., & Herrlich, P. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00916.x · Cited by 514 · cited 2×
“How does overexpression activate EGFR in the absence of a bound ligand? As described above, the inhibition of protein tyrosine phosphatases spontaneously activates EGFR in the absence of the ligand to the maximum level induced by EGF binding [52].”
BackgroundShoyab, M., De Larco, J. E., & Todaro, G. J. (1979) · Nature · doi:10.1038/279387a0 · Cited by 504 · cited 1×
“It has long been recognized that phosphorylation of EGFR T678 (T654 in mature EGFR) leads to decreased affinity of EGF and loss of EGF-stimulated receptor autophosphorylation [78-82].”
BackgroundThe EGFR Family: Not So Prototypical Receptor Tyrosine Kinases
Lemmon, M. A., Schlessinger, J., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 475 · cited 1×
“Excellent reviews have recently been published on the mechanism of activation of EGFR based on the ligand-induced dimerization model [25-29].”
BackgroundStructure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447 · cited 1×
“The “β-hairpin” of Subdomain II is buried and interacts with a “tethering arm” (also called “C1 modules” or “a pocket”) at the C-terminal end of Subdomain IV to form an “auto-inhibited” conformation [58,60,61].”
Nagane, M., Coufal, F. J., Lin, H., Bögler, O., Cavenee, W. K., & Huang, H.-J. S. (1996) · PubMed · Cited by 405
Gebhardt, F., Zänker, K. S., & Brandt, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13176 · Cited by 372 · cited 1×
“The number of polymorphic CA dinucleotide repeats in the intron 1 of EGFR, close to the enhancer region, seems to be involved in the regulation of EGFR transcription since transcription declines with increasing numbers of CA repeats [108-110].”
BackgroundA Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
Kovacs, E., Zorn, J. A., Huang, Y., Barros, T., & Kuriyan, J. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034402 · Cited by 371 · cited 1×
“Excellent reviews have recently been published on the mechanism of activation of EGFR based on the ligand-induced dimerization model [25-29].”
BackgroundStructure-Based View of Epidermal Growth Factor Receptor Regulation
Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368 · cited 1×
“Crystal structures of the extracellular domain of unliganded and ligand-bound EGFR have revealed large conformational changes [14,15,58,59].”
BackgroundLee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 367 · cited 1×
“The L861Q mutation (L837Q in mature EGFR) found in NSCLC is also in the A-loop of the kinase domain [122].”
BackgroundAllosteric regulation of the epidermal growth factor receptor kinase.
Schlessinger, J. (1986) · The Journal of cell biology · doi:10.1083/jcb.103.6.2067 · Cited by 365 · cited 1×
“It has long been thought that the two classes would be EGFR monomers and dimers with low and high affinity, respectively [68,69].”
BackgroundShan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012) · Cell · doi:10.1016/j.cell.2012.02.063 · Cited by 357 · cited 2×
“The R776H mutant receptor preferentially adopts the “receiver” position when paired with wild-type EGFR [138], providing support for the “superacceptor” hypothesis [139,140].”
BackgroundBhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005) · Modern Pathology · doi:10.1038/modpathol.3800438 · Cited by 355 · cited 1×
“Amplification of the EGFR gene is one way to overproduce EGFR, and has been observed in various cancers including breast carcinomas [100], non-small-cell lung cancer (NSCLC) [101], and glioblastoma multiforme (GBM) [102,103].”
BackgroundMoriki, T., Maruyama, H., & Maruyama, I. N. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4923 · Cited by 337 · cited 2×
“Ligand binding to the extracellular domain of the EGFR dimer induces ~140◦ rotation of the transmembrane domain, parallel to the plane of the cell membrane [37], as observed in many other cell-surface receptors [36,85,86].”
BackgroundSelf-citationEGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080083 · Cited by 323 · cited 1×
“EGFRvIVa lacks exons 25–27 (from G983 to P1090; from G959 to P1066 in mature EGFR), and EGFRvIVb lacks exons 25 and 26 (from G983 to G1054; from G959 to G1030 in mature EGFR) [113,151,152].”
BackgroundThe Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Red Brewer, M., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 317
Chou, T.-Y., Chiu, C.-H., Li, L.-H., Hsiao, C.-Y., Tzen, C.-Y., Chang, K.-T., Chen, Y.-M., Perng, R.-P., Tsai, S.-F., & Tsai, C.-M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 317 · cited 1×
“Two other mutations are a deletion in which residues from L747 to P753 (L723–P729 in mature EGFR) are replaced with a single serine to give the ∆L747–P753insS mutant [133,135,136], and the mutant ∆S752–I759 (∆S728–I735 in mature EGFR) in which residues 752–759 are deleted [133].”
BackgroundDifferential effects of EGFR ligands on endocytic sorting of the receptor
Roepstorff, K., Grandal, M. V., Henriksen, L., Knudsen, S. L. J., Lerdrup, M., Grøvdal, L., Willumsen, B. M., & Van Deurs, B. (2009) · Traffic · doi:10.1111/j.1600-0854.2009.00943.x · Cited by 310 · cited 1×
“This is partly due to the different binding affinities of the distinct ligands for EGFR [93,94].”
BackgroundMechanisms for oncogenic activation of the epidermal growth factor receptor
Zandi, R., Larsen, A. B., Andersen, P., Stockhausen, M.-T., & Poulsen, H. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.023 · Cited by 303 · cited 1×
“There are a number of mechanisms by which the tight regulation of EGFR signaling can be abrogated, including the enhanced production of ligands, overproduction of the EGFR protein, mutations leading to the constitutive activation of EGFR, deficiency of EGFR downregulation, and the activation of EGFR through cross-talk…”
BackgroundEGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Francis, J. M., Zhang, C.-Z., Maire, C. L., Jung, J., Manzo, V. E., Adalsteinsson, V. A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0879 · Cited by 287 · cited 1×
“Constitutive phosphorylation of EGFRvII at the level similar to that of wild-type EGFR stimulated with EGF was observed in serum starved cells, demonstrating ligand-independent activation [115].”
BackgroundFunctional selectivity of EGF family peptide growth factors: Implications for cancer
Wilson, K. J., Gilmore, J. L., Foley, J., Lemmon, M. A., & Riese, D. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.008 · Cited by 285
Downward, J., Waterfield, M. D., & Parker, P. J. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38602-7 · Cited by 282 · cited 1×
“It has long been recognized that phosphorylation of EGFR T678 (T654 in mature EGFR) leads to decreased affinity of EGF and loss of EGF-stimulated receptor autophosphorylation [78-82].”
BackgroundRegulation and targets of receptor tyrosine kinases
Pawson, T. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80597-4 · Cited by 264
Clayton, A. H. A., Walker, F., Orchard, S. G., Henderson, C., Fuchs, D., Rothacker, J., Nice, E. C., & Burgess, A. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504770200 · Cited by 256 · cited 10×
“It has been proposed that dimer-to-tetramer transition is required for full activation of the receptor, in which two dimers become juxtaposed in a side-by-side arrangement [40,88,89].”
BackgroundInfluentialAmador, M. L., Oppenheimer, D., Perea, S., Maitra, A., Cusati, G., Iacobuzio-Donahue, C., Baker, S. D., Ashfaq, R., Takimoto, C., Forastiere, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1036 · Cited by 241 · cited 1×
“The number of polymorphic CA dinucleotide repeats in the intron 1 of EGFR, close to the enhancer region, seems to be involved in the regulation of EGFR transcription since transcription declines with increasing numbers of CA repeats [108-110].”
BackgroundYu, X., Sharma, K. D., Takahashi, T., Iwamoto, R., & Mekada, E. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-08-0411 · Cited by 221 · cited 2×
“How is the EGFR dimer activated by ligand binding? It is known that the EGFR dimer is formed through an interaction of the intracellular domain [38,48], the transmembrane domain [83,84], and the extracellular C-terminal region of Subdomain IV [58,62].”
BackgroundCochet, C., Kashles, O., Chambaz, E. M., Borrello, I., King, C. R., & Schlessinger, J. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69070-2 · Cited by 217 · cited 1×
“Similar results are also obtained by the chemical cross-linking of EGFR expressed in living cells [32].”
ResultLigand-induced ErbB receptor dimerization
Lemmon, M. A. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.024 · Cited by 216 · cited 1×
“The extracellular ligand-binding domain of EGFR contains four distinct Subdomains I-IV [11-15].”
BackgroundMechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
Maruyama, I. (2014) · Cells · doi:10.3390/cells3020304 · Cited by 215 · cited 2×
“EGFR is a single-pass transmembrane protein, consisting of an extracellular domain, a transmembrane domain, a juxtamembrane (JM) segment, a kinase domain, and a C-terminal regulatory tail (Figure 1) [8,9].”
BackgroundSelf-citationAll EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells
Tao, R.-H., & Maruyama, I. N. (2008) · Journal of Cell Science · doi:10.1242/jcs.033399 · Cited by 206 · cited 4×
“In fact, the dimers are formed in the endoplasmic reticulum before reaching the cell surface [48], and the dimer formation does not depend on expression levels of the receptor [39,43,45].”
BackgroundInfluentialSelf-citationMechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding.
Böni-Schnetzler, M., & Pilch, P. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.22.7832 · Cited by 205 · cited 1×
“EGFR has a dimeric structure The epidermal growth factor receptor was one of the first receptors for which ligand-induced dimerization was proposed as the molecular mechanism of transmembrane signaling [30,31].”
BackgroundEGFR oligomerization organizes kinase-active dimers into competent signalling platforms
Needham, S. R., Roberts, S. K., Arkhipov, A., Mysore, V. P., Tynan, C. J., Zanetti-Domingues, L. C., Kim, E. T., Losasso, V., Korovesis, D., Hirsch, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms13307 · Cited by 203
Saffarian, S., Li, Y., Elson, E. L., & Pike, L. J. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.105494 · Cited by 201 · cited 1×
“Hetero-Förster resonance energy transfer (FRET) [39-41], fluorescence correlation spectroscopy [39-44] and homo-FRET [45,46] analyses also demonstrate that EGFR exists in dimeric form at physiological expression levels.”
BackgroundMolecular basis for multimerization in the activation of the epidermal growth factor receptor
Huang, Y., Bharill, S., Karandur, D., Peterson, S. M., Marita, M., Shi, X., Kaliszewski, M. J., Smith, A. W., Isacoff, E. Y., & Kuriyan, J. (2016) · eLife · doi:10.7554/elife.14107 · Cited by 193 · cited 3×
“More recently, EGFR-eGFP expressed in Xenopus oocytes at low levels, ~1 to ~5 molecules per μm2, existed in monomeric form when analyzed by photobleaching [56].”
BackgroundInfluentialThe extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand
Bouyain, S., Longo, P. A., Li, S., Ferguson, K. M., & Leahy, D. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507591102 · Cited by 192 · cited 1×
“The “β-hairpin” of Subdomain II is buried and interacts with a “tethering arm” (also called “C1 modules” or “a pocket”) at the C-terminal end of Subdomain IV to form an “auto-inhibited” conformation [58,60,61].”
Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor
Alvarado, D., Klein, D. E., & Lemmon, M. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.015 · Cited by 189 · cited 1×
“Crystal structures of the extracellular domain of Drosophila EGFR also suggest negative cooperativity in its ligand binding [74].”
BackgroundJiang, J., Greulich, H., Jänne, P. A., Sellers, W. R., Meyerson, M., & Griffin, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1829 · Cited by 186
CHU, C. T., EVERISS, K. D., WIKSTRAND, C. J., BATRA, S. K., KUNG, H.-J., & BIGNER, D. D. (1997) · Biochemical Journal · doi:10.1042/bj3240855 · Cited by 184
Transcriptional Activation of the Human Epidermal Growth Factor Receptor Promoter by Human p53
Ludes-Meyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., & Deb, S. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6009 · Cited by 182 · cited 1×
“It has been shown that wild-type and mutant p53 proteins directly activate EGFR transcription by specific binding to its promoter [104,105].”
BackgroundHeterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system
Macdonald, J. L., & Pike, L. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707080105 · Cited by 179 · cited 1×
“However, the heterogeneity in EGF-binding affinities has recently been shown to arise from negative cooperativity in the ligand-receptor interaction [70,71], which had been previously predicted [72].”
BackgroundSorkin, A., Mazzotti, M., Sorkina, T., Scotto, L., & Beguinot, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13377 · Cited by 168 · cited 1×
“This helix is a recognition element in EGFR by the AP-2 clathrin adaptor protein [65].”
BackgroundMutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy
Chan, S. K., Gullick, W. J., & Hill, M. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.031 · Cited by 167 · cited 8×
“Deletion mutants in the intracellular domain have also been found in NSCLC, and various deletions within the range encompassing E746 to I759 (E722 to I735 in mature EGFR) have been identified [133].”
BackgroundInfluentialSingle‐molecule analysis of epidermal growth factor binding on the surface of living cells
Teramura, Y., Ichinose, J., Takagi, H., Nishida, K., Yanagida, T., & Sako, Y. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601308 · Cited by 165 · cited 1×
“Single-molecule observation with total internal reflection fluorescence (TIRF) microscopy using oblique illumination also indicates the existence of dimers in living cells [47].”
BackgroundLiu, P., Sudhaharan, T., Koh, R. M. L., Hwang, L. C., Ahmed, S., Maruyama, I. N., & Wohland, T. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.102087 · Cited by 164 · cited 2×
“In fact, the dimers are formed in the endoplasmic reticulum before reaching the cell surface [48], and the dimer formation does not depend on the expression levels of the receptor [39,43,45].”
BackgroundSelf-citationHomo-FRET Imaging Enables Quantification of Protein Cluster Sizes with Subcellular Resolution
Bader, A. N., Hofman, E. G., Voortman, J., van Bergen en Henegouwen, P. M. P., & Gerritsen, H. C. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2009.07.059 · Cited by 160 · cited 2×
“As described above, FRET between fluorophores tagged at the C-terminus of EGFR demonstrates the existence of preformed EGFR dimers in the absence of a bound ligand [39,40,46].”
BackgroundConstitutive Activation of c-Jun N-terminal Kinase by a Mutant Epidermal Growth Factor Receptor
Antonyak, M. A., Moscatello, D. K., & Wong, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.5.2817 · Cited by 159 · cited 2×
“Among them, mutants with a deletion of exon 25 (from G983 to L1038; from G959 to L1014 in mature EGFR) or both exons 25 and 26 (from G983 to G1054; from G959 to G1030 in mature EGFR, which is equivalent to EGFRvIVb above) are constitutively phosphorylated, and cause phosphorylation of downstream STAT3 when expressed i…”
BackgroundA single ligand is sufficient to activate EGFR dimers
Liu, P., Cleveland, T. E., Bouyain, S., Byrne, P. O., Longo, P. A., & Leahy, D. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201114109 · Cited by 159 · cited 1×
“Consistent with this, single ligand binding seems to be sufficient to activate the EGFR dimer [75].”
BackgroundThiel, K. W., & Carpenter, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703854104 · Cited by 158 · cited 1×
“It has long been recognized that phosphorylation of EGFR T678 (T654 in mature EGFR) leads to decreased affinity of EGF and loss of EGF-stimulated receptor autophosphorylation [78-82].”
BackgroundMagun, B. E., Matrisian, L. M., & Bowden, G. T. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43747-7 · Cited by 155
Novel mechanisms of RTK signal generation
Weiß, F. U., Daub, H., & Ullrich, A. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80113-x · Cited by 151 · cited 1×
“Furthermore, a modified model has proposed that the receptor monomers are at equilibrium with receptor dimers [33,34].”
BackgroundEGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes
Grandal, M. V., Zandi, R., Pedersen, M. W., Willumsen, B. M., van Deurs, B., & Poulsen, H. S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm058 · Cited by 150 · cited 1×
“EGFRvIII fails to be ubiquitinated, thus prolonging oncogenic signaling [119].”
BackgroundMechanism for activation of mutated epidermal growth factor receptors in lung cancer
Red Brewer, M., Yun, C.-H., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 148 · cited 3×
“The R776H mutant receptor preferentially adopts the “receiver” position when paired with wild-type EGFR [138], providing support for the “superacceptor” hypothesis [139,140].”
BackgroundMacdonald-Obermann, J. L., & PIKE, L. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586826 · Cited by 145 · cited 1×
“This is partly due to the different binding affinities of the distinct ligands for EGFR [93,94].”
BackgroundEGFR ligands exhibit functional differences in models of paracrine and autocrine signaling
Wilson, K. J., Mill, C., Lambert, S., Buchman, J., Wilson, T. R., Hernandez-Gordillo, V., Gallo, R. M., Ades, L. M. C., Settleman, J., & Riese, D. J. (2012) · Growth Factors · doi:10.3109/08977194.2011.649918 · Cited by 131
Gallant, J.-N., Sheehan, J. H., Shaver, T. M., Bailey, M., Lipson, D., Chandramohan, R., Brewer, M. R., York, S. J., Kris, M. G., Pietenpol, J. A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0654 · Cited by 126 · cited 2×
“Computational modeling suggests that EGFR-KDD can be activated by virtue of an asymmetric intramolecular dimeric structure, unlike the typical asymmetric, intermolecular dimeric structure between adjacent protomers [149].”
BackgroundBae, J. H., & Schlessinger, J. (2010) · Molecules and Cells · doi:10.1007/s10059-010-0080-5 · Cited by 125 · cited 1×
“Excellent reviews have recently been published on the mechanism of activation of EGFR based on the ligand-induced dimerization model [25-29].”
BackgroundCho, J., Chen, L., Sangji, N., Okabe, T., Yonesaka, K., Francis, J. M., Flavin, R. J., Johnson, W., Kwon, J., Yu, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1145 · Cited by 117 · cited 1×
“An asymmetric configuration of the kinase domain dimer is required for the ligand-independent activity of NSCLC-associated EGFR kinase mutants [140,145].”
BackgroundMartin-Fernandez, M. L., Clarke, D. T., Tobin, M. J., Jones, S. V., & Jones, G. R. (2002) · Biophysical Journal · doi:10.1016/s0006-3495(02)75585-9 · Cited by 115 · cited 7×
“Therefore, FRET between fluorophores tagged at the N-terminus of EGFR does not correctly report whether EGFR is monomeric or dimeric, since FRET is dramatically changed before and after ligand binding.”
BackgroundInfluentialDisabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics
Berezov, A., Chen, J., Liu, Q., Zhang, H., Greene, M. I., & Murali, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202880200 · Cited by 104 · cited 2×
“How is the EGFR dimer activated by ligand binding? It is known that the EGFR dimer is formed through an interaction of the intracellular domain [38,48], the transmembrane domain [83,84], and the extracellular C-terminal region of Subdomain IV [58,62].”
BackgroundLigand-induced EGF Receptor Oligomerization Is Kinase-dependent and Enhances Internalization
Hofman, E. G., Bader, A. N., Voortman, J., van den Heuvel, D. J., Sigismund, S., Verkleij, A. J., Gerritsen, H. C., & Henegouwen, P. M. P. V. B. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164731 · Cited by 104 · cited 4×
“In fact, the dimers are formed in the endoplasmic reticulum before reaching the cell surface [48], and the dimer formation does not depend on the expression levels of the receptor [39,43,45].”
BackgroundMethodInfluentialInterdependent epidermal growth factor receptor signalling and trafficking
Jones, S., & Rappoport, J. Z. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.014 · Cited by 102 · cited 3×
“EGFR activates several downstream signaling cascades, which include pathways mediated by Ras/Raf/MAP kinase, phosphoinositide-3-kinase (PI3K)/Akt, and phospholipase Cγ [10,24].”
BackgroundHumphrey, P. A., Gangarosa, L. M., Wong, A. J., Archer, G. E., Lund‐Johansen, M., Bjerkvig, R., Laerum, O.-D., Friedman, H. S., & Bigner, D. D. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91051-d · Cited by 99
Valley, C. C., Arndt‐Jovin, D. J., Karedla, N., Steinkamp, M. P., Chizhik, A. I., Hlavacek, W. S., Wilson, B. S., Lidke, K. A., & Lidke, D. S. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-05-0269 · Cited by 98 · cited 3×
“In this ligand-independent activation of EGFR due to L858R, “β-hairpin” interaction of the extracellular Subdomain II plays a critical role [54].”
BackgroundBocharov, E. V., Mineev, K. S., Pavlov, K. V., Akimov, S. A., Kuznetsov, A. S., Efremov, R. G., & Arseniev, A. S. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.10.024 · Cited by 96 · cited 1×
“Mechanism of Activation of EGFR dimers by ligand binding: The “rotation model” How is the EGFR dimer activated by ligand binding? It is known that the EGFR dimer is formed through interaction of the intracellular domain [38,48], the transmembrane domain [83,84], and the extracellular C-terminal region of Subdomain IV…”
BackgroundBocharov, E. V., Lesovoy, D. M., Pavlov, K. V., Pustovalova, Y. E., Bocharova, O. V., & Arseniev, A. S. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.02.023 · Cited by 95 · cited 1×
“This rotation of the transmembrane domain is supported by an NMR structural study showing that the transmembrane domain of EGFR has two surfaces through which the domains interact with each other [87].”
BackgroundChoi, S. H., Mendrola, J. M., & Lemmon, M. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209957 · Cited by 93 · cited 4×
“through the release of the A-loop from the active site for substrate binding [128].”
BackgroundInfluentialSaito, T., Okada, S., Ohshima, K., Yamada, E., Sato, M., Uehara, Y., Shimizu, H., Pessin, J. E., & Mori, M. (2004) · Endocrinology · doi:10.1210/en.2004-0401 · Cited by 89 · cited 1×
“For example, TGFα and AREG stimulate proliferation of 32D cells more efficiently than do EGF and HB-EGF, and these efficiency differences have been correlated with differential phosphorylation of specific sites on the Cterminal tail of EGFR [90-92].”
BackgroundJeuken, J. W. M., Sijben, A. E. J., Alenda, C., Rijntjes, J., Dekkers, M. M. G., Boots‐Sprenger, S., McLendon, R. E., & Wesseling, P. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00320.x · Cited by 85 · cited 1×
“As described above, a large fraction of GBM cells display EGFR gene amplification that correlates with receptor overexpression [102], and also exhibit an EGFRvIII deletion mutation in the extracellular domain of the receptor [150].”
BackgroundPedersen, M. W., Tkach, V., Pedersen, N. M., Berezin, V., & Poulsen, H. S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11566 · Cited by 85 · cited 1×
“The aberrant activation of EGFR is often associated with the overexpression of the EGFR gene [97,98].”
BackgroundMacdonald-Obermann, J. L., & Pike, L. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.001487 · Cited by 84 · cited 1×
“However, the heterogeneity in EGF-binding affinities has recently been shown to arise from negative cooperativity in the ligand-receptor interaction [70,71], which had been previously predicted [72].”
BackgroundPredominance of activated EGFR higher-order oligomers on the cell surface
Clayton, A. H. A., Orchard, S. G., Nice, E. C., Posner, R. G., & Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802442187 · Cited by 83 · cited 2×
“As described above, tetramerization and oligomerization are required for full activation of the receptor, in which two dimers become juxtaposed in a side-by-side arrangement [40,88,89].”
BackgroundCho, J., Pastorino, S., Zeng, Q., Xu, X., Johnson, W., Vandenberg, S., Verhaak, R., Cherniack, A. D., Watanabe, H., Dutt, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0821 · Cited by 74 · cited 1×
“Recent genomic studies in GBM and NSCLC patients have identified an additional class of oncogenic mutations caused by deletion of C-terminal coding regions [103,154-156].”
BackgroundImplications of epidermal growth factor (EGF) induced egf receptor aggregation
Wofsy, C., Goldstein, B., Lund, K., & Wiley, H. S. (1992) · Biophysical Journal · doi:10.1016/s0006-3495(92)81572-2 · Cited by 73 · cited 1×
“However, the heterogeneity in EGF-binding affinities has recently been shown to arise from negative cooperativity in the ligand-receptor interaction [70,71], which had been previously predicted [72].”
BackgroundActivation of transmembrane cell‐surface receptors via a common mechanism? The “rotation model”
Maruyama, I. N. (2015) · BioEssays · doi:10.1002/bies.201500041 · Cited by 72 · cited 2×
“Ligand binding to the extracellular domain of the EGFR dimer induces ~140◦ rotation of the transmembrane domain, parallel to the plane of the cell membrane [37], as observed in many other cell-surface receptors [36,85,86].”
BackgroundSelf-citationGilmer, T. M., Cable, L., Alligood, K. J., Rusnak, D. W., Spehar, G. M., Gallagher, K. T., Woldu, E., Carter, H. L., Truesdale, A. T., Shewchuk, L. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2404 · Cited by 70 · cited 1×
“A deletion mutant, ∆E746–A750 (∆E722–A726 in mature EGFR), is constitutively phosphorylated in the absence of the ligand [134].”
BackgroundEGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism
Pines, G., Huang, P. H., Zwang, Y., White, F. M., & Yarden, Y. (2010) · Oncogene · doi:10.1038/onc.2010.313 · Cited by 69 · cited 1×
“The oncogenic function of these mutants depends upon the intrinsic kinase activity [153].”
BackgroundMacdonald-Obermann, J. L., Piwnica-Worms, D. R., & PIKE, L. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111316109 · Cited by 68 · cited 1×
“Results of reversible firefly luciferase enzyme fragment complementation [49-51] and homo-FRET [45] analyses demonstrate that EGFR exists in dimeric form at the cell surface, since no fluorescence intensity increase is observed upon addition of EGF to the cell culture.”
BackgroundEnergetics of ErbB1 Transmembrane Domain Dimerization in Lipid Bilayers
Chen, L., Merzlyakov, M., Cohen, T., Shai, Y., & Hristova, K. A. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2009.03.004 · Cited by 63 · cited 1×
“How is the EGFR dimer activated by ligand binding? It is known that the EGFR dimer is formed through an interaction of the intracellular domain [38,48], the transmembrane domain [83,84], and the extracellular C-terminal region of Subdomain IV [58,62].”
BackgroundEpidermal growth factor receptor activation in prostate cancer by three novel missense mutations
Cai, C. Q., Peng, Y., Buckley, M. T., Wei, J., Chen, F. F., Liebes, L., Gerald, W. L., Pincus, M. R., Osman, I., & Lee, P. (2008) · Oncogene · doi:10.1038/sj.onc.1210983 · Cited by 63 · cited 1×
“G735S, G796S, and E804G mutations (G711S, G772S, and E780G in mature EGFR) found in prostate cancer are oncogenic, causing increased cell growth, transformation, and invasion [141].”
BackgroundPedersen, M. W., Pedersen, N. M., Damstrup, L., Villingshøj, M., Sønder, S. U., Rieneck, K., Bovin, L. F., Spang‐Thomsen, M., & Poulsen, H. S. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20554 · Cited by 62 · cited 3×
“Among them, mutants with a deletion of exon 25 (from G983 to L1038; from G959 to L1014 in mature EGFR) or both exons 25 and 26 (from G983 to G1054; from G959 to G1030 in mature EGFR, which is equivalent to EGFRvIVb above) are constitutively phosphorylated, and cause phosphorylation of downstream STAT3 when expressed i…”
BackgroundChrysogelos, S. A. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.24.5736 · Cited by 62 · cited 1×
“A specific region of EGFR has an enhancer activity in breast cancer cell lines overproducing EGFR [106,107].”
Backgroundvan Noesel, J., van der Ven, W. H., van Os, T. A. M., Kunst, P. W. A., Weegenaar, J., Reinten, R. J. A., Kancha, R. K., Duyster, J., & van Noesel, C. J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.1586 · Cited by 60 · cited 2×
“This mutant receptor is constitutively autophosphorylated in the absence of the ligand [137,138].”
BackgroundPutting together structures of epidermal growth factor receptors
Bessman, N. J., Freed, D. M., & Lemmon, M. A. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.10.002 · Cited by 57 · cited 1×
“Excellent reviews have recently been published on the mechanism of activation of EGFR based on the ligand-induced dimerization model [25-29].”
BackgroundJohnston, D., Hall, H., DiLorenzo, T. P., & Steinberg, B. M. (1999) · PubMed · Cited by 57
Recruitment of the Adaptor Protein Grb2 to EGFR Tetramers
Kozer, N., Barua, D., Henderson, C. A., Nice, E. C., Burgess, A. W., Hlavacek, W. S., & Clayton, A. H. A. (2014) · Biochemistry · doi:10.1021/bi500182x · Cited by 52 · cited 2×
“As described above, tetramerization and oligomerization are required for full activation of the receptor, in which two dimers become juxtaposed in a side-by-side arrangement [40,88,89].”
BackgroundWard, C. W., & Garrett, T. (2001) · BMC Bioinformatics · doi:10.1186/1471-2105-2-4 · Cited by 51 · cited 1×
“(also known as L1) and III (or L2) have a β-helix solenoid structure, which is related to the leucine-rich repeat superfamily [16], and are responsible for ligand binding through simultaneous contact to the same bound ligand.”
BackgroundArjona, D., Bello, M. J., Alonso, M. E., Amiñoso, C., Isla, A., de Campos, J. M., Sarasa, J. L., Gutierrez, M., Villalobo, A., & REY, J. A. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00653.x · Cited by 48 · cited 1×
“Missense mutations (R108K, T263P, A289V and G598V; R84K, T239P, A265V and G574V in mature EGFR) in the extracellular domain of EGFR were also found in GBM and glioblastoma cell lines, which conferred anchorage-independent growth and tumorigenicity upon NIH 3T3 cells [113,121,123].”
BackgroundSheikh, M. S., Carrier, F., Johnson, A. C., Ogdon, S. E., & Fornace, A. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201264 · Cited by 47 · cited 1×
“It has been shown that wildtype and mutant p53 proteins directly activate EGFR transcription by specific binding to its promoter [104,105].”
BackgroundMacdonald-Obermann, J. L., Adak, S., Landgraf, R., Piwnica-Worms, D. R., & PIKE, L. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.489534 · Cited by 44 · cited 1×
“Results of reversible firefly luciferase enzyme fragment complementation [49-51] and homo-FRET [45] analyses demonstrate that EGFR exists in dimeric form at the cell surface, since no fluorescence intensity increase is observed upon addition of EGF to the cell culture.”
BackgroundCurran, T. G., Zhang, Y., Ma, D. J., Sarkaria, J. N., & White, F. M. (2015) · Nature Communications · doi:10.1038/ncomms6924 · Cited by 44 · cited 1×
“For example, TGFα and AREG stimulate proliferation of 32D cells more efficiently than do EGF and HB-EGF, and these efficiency differences have been correlated with differential phosphorylation of specific sites on the Cterminal tail of EGFR [90-92].”
BackgroundYang, K. S., Ilagan, M. X. G., Piwnica-Worms, D. R., & PIKE, L. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808041200 · Cited by 42 · cited 1×
“Results of reversible firefly luciferase enzyme fragment complementation [49-51] and homo-FRET [45] analyses demonstrate that EGFR exists in dimeric form at the cell surface, since no fluorescence intensity increase is observed upon addition of EGF to the cell culture.”
BackgroundSchwentner, I. M., Witsch‐Baumgartner, M., Sprinzl, G. M., Krugmann, J., Tzankov, A., Jank, S., Zwierzina, H., & Löffler‐Ragg, J. (2008) · Head & Neck · doi:10.1002/hed.20831 · Cited by 39 · cited 1×
“The G735S and G796S mutations were also found in thyroid cancer and squamous cell carcinoma of the head and neck, respectively [142,143].”
BackgroundMechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase
Ruan, Z., & Kannan, N. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00444 · Cited by 38 · cited 2×
“The R776H mutant receptor preferentially adopts the “receiver” position when paired with wild-type EGFR [138], providing support for the “superacceptor” hypothesis [139,140].”
BackgroundEpidermal growth factor receptor extracellular domain mutations in primary glioblastoma
Idbaïh, A., Aimard, J., Boisselier, B., Marie, Y., Paris, S., Crinière, E., Silva, R. C., Laigle–Donadey, F., Rousseau, A., Mokhtari, K., et al. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.00977.x · Cited by 37 · cited 1×
“All these cysteines are present in Subdomain IV [113,124-126].”
BackgroundBocharov, E. V., Sharonov, G. V., Bocharova, O. V., & Pavlov, K. V. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.01.025 · Cited by 36 · cited 1×
“Ligand binding to the extracellular domain of the EGFR dimer induces ~140◦ rotation of the transmembrane domain, parallel to the plane of the cell membrane [37], as observed in many other cell-surface receptors [36,85,86].”
BackgroundReceptor tyrosine kinase signaling mechanisms: Devolving TrkA responses with phosphoproteomics
Bradshaw, R. A., Chalkley, R. J., Biarc, J., & Burlingame, A. L. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.10.006 · Cited by 31 · cited 1×
“The intracellular domain of EGFR has 20 tyrosine residues, 12 of which are known to be phosphorylated [18-20].”
BackgroundTong, J., Taylor, P. P., Jovceva, E., St‐Germain, J. R., Jin, L. L., Nikolic, A., Gu, X., Li, Z. H., Trudel, S., & Moran, M. F. (2008) · Journal of Proteome Research · doi:10.1021/pr7006363 · Cited by 30 · cited 1×
“The intracellular domain of EGFR has 20 tyrosine residues, 12 of which are known to be phosphorylated [18-20].”
BackgroundThe Epidermal Growth Factor Receptor Forms Location-Dependent Complexes in Resting Cells
Yavas, S., Macháň, R., & Wohland, T. (2016) · Biophysical Journal · doi:10.1016/j.bpj.2016.09.049 · Cited by 30 · cited 2×
“This is inconsistent with previous results in which the EGFR expressed in CHO cells at low levels, ~3 molecules per μm2, was present in dimeric form [43].”
BackgroundResultYamashita, H., Yano, Y., Kawano, K., & Matsuzaki, K. (2015) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.03.004 · Cited by 29 · cited 1×
“FRET analysis of EGFR fluorescently tagged at its N-terminus suggested that a majority of EGFR molecules were present in monomeric form [53].”
BackgroundReceptor Guanylyl Cyclases in Sensory Processing
MARUYAMA, I. N. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00173 · Cited by 27 · cited 1×
“Ligand binding to the extracellular domain of the EGFR dimer induces ~140° rotation of the transmembrane domain, parallel to the plane of the cell membrane [37], as observed in many other cell-surface receptors [36,85,86].”
BackgroundSelf-citationAdak, S., Yang, K. S., Macdonald-Obermann, J. L., & PIKE, L. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274175 · Cited by 27 · cited 3×
“The deletion of JM-A results in the complete loss of negative cooperativity in ligand binding to EGFR [77].”
BackgroundInfluentialGreenall, S. A., Donoghue, J. F., Gottardo, N. G., Johns, T. G., & Adams, T. E. (2014) · Oncogene · doi:10.1038/onc.2014.106 · Cited by 24 · cited 3×
“Indeed, EGFRvIII spontaneously forms cysteine disulfide-bridged dimers that are phosphorylated in the absence of the ligand [121].”
BackgroundInfluentialOzer, B. H., Wiepz, G. J., & Bertics, P. J. (2009) · Oncogene · doi:10.1038/onc.2009.385 · Cited by 21 · cited 1×
“This duplication region comprising exons 1826 encodes the entire kinase domain, and the mutant designated “TKD-EGFR” displays chronically elevated basal autophosphorylation at five known phosphorylation sites [148].”
BackgroundThe Tethering Arm of the EGF Receptor Is Required for Negative Cooperativity and Signal Transduction
Adak, S., DeAndrade, D. S., & PIKE, L. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.182899 · Cited by 19 · cited 2×
“There is evidence that the interaction between the “tethering arms” (Residues 585–609 of Subdomain IV; 561–585 in mature EGFR) in the extracellular domains of the EGFR dimer is essential for negative cooperativity in EGF binding [76].”
BackgroundFurgason, J. M., Li, W., Milholland, B., Cross, E., Li, Y., McPherson, C. M., Warnick, R. E., Rixe, O., Stambrook, P. J., Vijg, J., et al. (2014) · Mutagenesis · doi:10.1093/mutage/geu026 · Cited by 18 · cited 8×
“Mutations in the C-Terminal Tail Region As described above, a large fraction of GBM cells display EGFR gene amplification that correlates with receptor overexpression [102], and also exhibit an EGFRvIII deletion mutation in the extracellular domain of the receptor [150].”
BackgroundInfluentialPark, A. K.-J., Francis, J. M., Park, W., Park, J.-O., & Cho, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3559 · Cited by 17 · cited 1×
“Among them, mutants with a deletion of exon 25 (from G983 to L1038; from G959 to L1014 in mature EGFR) or both exons 25 and 26 (from G983 to G1054; from G959 to G1030 in mature EGFR, which is equivalent to EGFRvIVb above) are constitutively phosphorylated, and cause phosphorylation of downstream STAT3 when expressed i…”
Background
Cited by
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles
Santos, E. D. S., Nogueira, K. A. B., Fernandes, L. C. C., Martins, J. R. P., Reis, A. V. F., Neto, J. D. B. V., Júnior, I. J. D. S., Pessoa, C., Petrilli, R., & Eloy, J. O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120082 · Cited by 185
Molecular Regulation and Oncogenic Functions of TSPAN8
Yang, J., Zhang, Z., Lam, J. S. W., Fan, H., & Fu, N. Y. (2024) · Cells · doi:10.3390/cells13020193 · Cited by 11
“The epidermal growth factor receptor (EGFR), which plays a crucial role in many key cellular processes such as cell proliferation, survival, motility, and differentiation [60], has been identified as a strong TSPAN8-binding partner [47].”
BackgroundCholesterol promotes the formation of dimers and oligomers of the receptor tyrosine kinase ROR1
Ward, A., Baeza-Ballesteros, L. J., Schuck, R., García-Murria, M. J., Lamichhane, R., Mingarro, I., & Barrera, F. N. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111000 · Cited by 4
Metadata
- Authors
- Purba, E., Saita, E.-I., & Maruyama, I.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2017-06-02
- Volume
- 6
- Issue
- 2
- Pages
- 13
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2620474869
- Cited by
- 205
- References
- 150
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.